

除本公告另有界定外，本公告中所用詞彙與藥捷安康(南京)科技股份有限公司(「**本公司**」)所刊發日期為2025年6月13日的招股章程(「**招股章程**」)所界定者具有相同涵義。香港交易及結算所有限公司、香港聯合交易所有限公司(「**香港聯交所**」)及香港中央結算有限公司(「**香港結算**」)對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本公告不會直接或間接於或向美國(包括其領土及屬地、美國任何州及哥倫比亞特區)發佈、發行、分派。本公告並非且不構成在美國或任何其他司法管轄區的任何銷售要約或購買或認購證券的招攬。發售股份未曾亦不會根據《1933年美國證券法》(經不時修訂)(「**美國證券法**」)或美國任何州的證券法登記。除非擁有有效登記聲明或獲豁免遵守美國證券法的登記規定或進行不受該證券法登記規定限制的交易，否則證券不得在美國提呈發售或出售。我們現時無意於美國公開發售證券。發售股份乃根據美國證券法S規例在美國境外以離岸交易方式發售及出售。

本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。有意投資者決定是否投資於H股前，應細閱招股章程以了解下文有關全球發售的詳細資料。



**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康(南京)科技股份有限公司**  
(於中華人民共和國註冊成立的股份有限公司)  
(股份代號：2617)

**澄清公告**

本公司董事會(「**董事會**」)有意修改本公司刊發日期為2025年6月20日的配發結果公告(「**配發結果公告**」)中英文版本的若干手民之誤。

請參閱隨附顯示澄清的配發結果公告黑線版本。澄清詳情載於「H股股東股權集中度分析」、「股權集中度分析」及「公眾持股量」(僅中文版本)的章節。

除隨附文件所顯示該等澄清外，配發結果公告所列的所有其他資料保持不變，且本公司確認配發結果公告並無任何重大錯誤陳述。

承董事會命  
藥捷安康(南京)科技股份有限公司  
董事長兼首席執行官  
吳永謙博士

香港，2025年6月22日

名列本公告相關申請的本公司董事為：(i)執行董事吳永謙博士及吳笛先生；(ii)非執行董事賈中新女士及易華博士；及(iii)獨立非執行董事李書湃先生、徐海音女士及鄭哲蘭女士。

香港交易及結算所有限公司、香港聯合交易所有限公司（「香港聯交所」）及香港中央結算有限公司（「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本公告不會直接或間接於或向美國（包括美國的領土及屬地、美國任何州以及哥倫比亞特區）發佈、刊發或派發。本公告並不構成亦不屬於在美國或於任何其他司法管轄區購買或認購證券的任何要約或招攬的一部分。本公告所述證券並無亦不會根據《1933年美國證券法》（經不時修訂）（「美國證券法」）或美國任何州證券法登記。證券不得在美國提呈發售或出售，惟獲豁免或無須遵守美國證券法登記規定除外。證券將不會於美國公開發售。

本公告僅作參考用途，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。潛在投資者應先行閱讀藥捷安康（南京）科技股份有限公司（「本公司」）所刊發日期為2025年6月13日的招股章程（「招股章程」）內有關下文所述全球發售的詳細資料，方決定是否投資於所提呈發售的股份。

除非本公告另有界定，否則本公告所用詞彙與招股章程所界定者具有相同涵義。

就全球發售而言，中信里昂證券有限公司作為穩定價格操作人（「穩定價格操作人」）或其聯屬人士或代其行事的任何人士可代表包銷商在香港或其他地方的適用法律及監管規定許可的範圍內進行交易，以於上市日期後一段有限期間內按穩定價格操作人、其聯屬人士或代其行事的任何人士可能釐定的方式以該等人士可能釐定的數額將股份市價穩定或維持在該等人士可能釐定的價格，並高於原本可能的水平。然而，穩定價格操作人（或其聯屬人士或代其行事的任何人士）均無責任進行任何該等穩定價格行動。該等穩定價格行動一經採取，(a)將由穩定價格操作人（或其聯屬人士或代其行事的任何人士）全權酌情以穩定價格操作人合理認為符合本公司最佳利益的方式進行；(b)可隨時終止；及(c)須於2025年7月18日（星期五）（即遞交香港公開發售申請截止日期後第30日）結束。該等穩定價格行動一經採取，可於所有獲准進行上述行動的司法管轄區進行，惟在任何情況下均須遵守所有適用法律、規則及監管規定，包括香港法例第571章《證券及期貨條例》項下的香港法例第571W章《證券及期貨（穩定價格）規則》（經修訂）。

潛在投資者務請注意，為維持股份價格而採取的穩定價格行動的時間不得超過穩定價格期，即由上市日期開始，並預期將於2025年7月18日（星期五）（即遞交香港公開發售申請截止日期後第30日）屆滿。於該日後，不得再採取任何穩定價格行動，因此股份需求及股份價格可能下跌。

發售股份的潛在投資者應注意，整體協調人（為其本身及代表香港包銷商）有權在招股章程「包銷－包銷安排及費用－終止理由」一段所載的任何事件發生後，於上市日期上午八時正（香港時間）之前隨時終止其於香港包銷協議項下的責任且即時生效。



**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康（南京）科技股份有限公司**  
(於中華人民共和國註冊成立的股份有限公司)

**全球發售**

全球發售項下的發售股份數目：**15,281,000股H股**  
香港發售股份數目：**3,057,000股H股**（經重新分配後調整）  
國際發售股份數目：**12,224,000股H股**（經重新分配後調整）  
發售價：**每股H股13.15港元，另加1.0%**  
**經紀佣金、0.0027% 證監會交易**  
**徵費、0.00015% 會財局交易徵費及**  
**0.00565% 香港聯交所交易費**（須於  
申請時以港元繳足，多繳股款可予  
退還）  
面值：**每股H股人民幣1.00元**  
股份代號：**2617**

**聯席保薦人、整體協調人、聯席全球協調人、**  
**聯席賬簿管理人及聯席牽頭經辦人**  
(排名不分先後)



**整體協調人、聯席全球協調人、**  
**聯席賬簿管理人及聯席牽頭經辦人**



**聯席賬簿管理人及聯席牽頭經辦人**



# TRANSTHERA SCIENCES (NANJING), INC. / 藥捷安康（南京）科技股份有限公司最終發售價及配發結果公告

除本公告另有界定者外，本公告所用詞彙與藥捷安康（南京）科技股份有限公司（「本公司」）日期為 2025 年 6 月 13 日的招股章程（「招股章程」）所界定者具有相同涵義。

**警告：**鑑於股權高度集中於數目不多之 H 股股東，即使少量 H 股成交，該公司之 H 股價格亦可能大幅波動，H 股股東及有意投資者於買賣該公司 H 股時務請審慎行事。

## 摘要

公司資料	
股份代號	2617
股份簡稱	TRANSTHERA-B
開始買賣日	2025 年 6 月 23 日*

\*請參閱本公告底部備註

價格資料	
固定發售價	港元 13.15
發售股份及股本	
發售股份數目	15,281,000
香港公開發售的最終發售股份數目	3,057,000
國際發售的最終發售股份數目	12,224,000
於上市時已發行的股份數目	396,897,633
所得款項	
所得款項總額(備註)	港元 200.95 百萬
減：固定發售價之預計應付上市費	港元(39.61)百萬
所得款項淨額	港元 161.34 百萬

備註：所得款項總額是指發行人有權收取的金額。有關所得款項用途的詳情，請參閱 2025 年 6 月 13 日的招股章程。

## 配發結果詳情

### 香港公開發售

有效申請數目	135,427
受理申請數目	6,114
認購額	3,419.87 倍
觸發回補機制	否
香港公開發售初步可供認購股份數目	1,528,500
由國際發售重新分配的股份數目	1,528,500
香港公開發售最終發售股份數目（在重新分配後）	3,057,000



香港公開發售的發售股份數目佔全球發售的發售股份數目之百分比	20.00%
-------------------------------	--------

有關向香港公開發售進行最終股份分配的詳細信息，投資者可以參考 <https://www.hkeipo.hk/iporesult/zh> 以名稱或標識號進行搜索，或者訪問 <https://www.hkeipo.hk/iporesult/zh> 以獲取已分配者的完整列表。

### 國際發售

承配人的數量	123
認購額	0.97 倍
國際發售的初步可供認購發售股份數目	13,752,500
重新分配至香港公開發售的發售股份數目	1,528,500
國際發售最終發售股份數目 (在重新分配後)	12,224,000
國際發售的發售股份數目佔全球發售的發售股份數目之百分比	80.00%

董事確認，據彼等所深知、盡悉及確信，除(a)聯交所根據配售指引第5(2)段授出同意，允許本公司向本公司現有股東的緊密聯繫人分配國際發售中的若干發售股份，及(b)聯交所根據配售指引第5(1)段及指南第4.15章就向一名關連客戶分配發售股份授出同意外，(i)承配人及公眾認購的發售股份並非由本公司、任何董事、本公司最高行政人員、監事、控股股東、主要股東、本公司現有股東或其任何附屬公司或彼等各自的緊密聯繫人直接或間接撥資，(ii)購買發售股份的承配人及公眾概無習慣受本公司、任何董事、本公司最高行政人員、監事、控股股東、主要股東、本公司現有股東或其任何附屬公司或彼等各自的緊密聯繫人的指示而對登記於其名下或其以其他方式持有的股份進行收購、出售、表決或其他處置。

國際發售的承配人包括以下：

### 基石投資者

投資者	所分配發售股份數目	佔發售股份數目之百分比	佔全球發售後已發行H股總數之百分比	佔全球發售後已發行股本總數之百分比	現有股東或其緊密聯繫人
Jiangbei Pharmaceutical Technology (Hong Kong) Limited / 江北醫藥科技（香港）有限公司	5,740,500	37.57%	1.90%	1.45%	是
Sinohsc Honest	1,642,000	10.75%	0.54%	0.41%	是

投資者	所分配發售股份 數目	佔發售股份 數目之百分 比	佔全球發售 後已發行H 股總數之百 分比	佔全球發售 後已發行股 本總數之百 分比	現有股東 或其緊密 聯繫人
Limited / 華 盛敦行有限公 司					
Pharmablock Horizon Capital Limited / 藥 石地平線資本 有限公司	821,500	5.38%	0.27%	0.21%	是
Kelingan (Hong Kong) Technology Co., Limited / 科瓏安 (香港) 科技 有限公司	817,500	5.35%	0.27%	0.21%	否
AKESO, INC. / 康方生物 科技(開曼) 有限公司	752,500	4.92%	0.25%	0.19%	否
總計	9,774,000	63.96%	3.24%	2.46%	

已獲得豁免/同意的獲配發人

投資者	所分配發售 股份數目	佔全球發售後已 發行H股總數之 百分比	佔全球發售後已 發行股本總數之 百分比	關係
根據配售指引第5(2)段就現有股東的緊密聯繫人認購股份獲得同意的獲配發人 <sup>備註2</sup>				
Jiangbei Pharmaceutical Technology Hong Kong Limited / 江北醫藥科技 (香港) 有限公 司	5,740,500	1.90%	1.45% <sup>備註1</sup>	現有股東的緊密 聯繫人並為基石 投資者
Sinohsc Honest Limited / 華盛敦 行有限公司	1,642,000	0.54%	0.41% <sup>備註1</sup>	現有股東的緊密 聯繫人並為基石 投資者
Pharmablock Horizon Capital Limited / 藥石地	821,500	0.27%	0.21% <sup>備註1</sup>	

投資者	所分配發售股份數目	佔全球發售後已發行H股總數之百分比	佔全球發售後已發行股本總數之百分比	關係
平線資本有限公司				現有股東的全資附屬公司並為基石投資者
總計	8,204,000	2.72%	2.07%	
根據配售指引第5(1)段就一名關連客戶認購股份獲得同意的獲配發人 <sup>備註3</sup>				
華泰資本投資有限公司	596,500	0.20%	0.15%	關連客戶

備註：

(1) 僅根據分配予各基石投資者的發售股份數目計算，不計及相關現有股東（有關基石投資者為其緊密聯繫人）所持有的股份數目。

(2) 在基石投資者中，(i) 江北醫藥科技（香港）有限公司為現有股東南京紫金、江北基金、南京其瑞佑康、江北資產管理、泰興啟辰及江蘇中德（各自定義見招股章程）（統稱為「江蘇股東」）的緊密聯繫人；(ii) 華盛敦行有限公司為現有股東江蘇敦和及蘇州敦行（各自定義見招股章程）的緊密聯繫人；及(iii) 藥石地平線資本有限公司為現有股東藥石（定義見招股章程）的全資附屬公司。聯交所已根據配售指引第5(2)段授予同意，允許向江北醫藥科技（香港）有限公司、華盛敦行有限公司及藥石地平線資本有限公司配售國際發售的H股。有關詳情，請參閱招股章程「豁免嚴格遵守《上市規則》及豁免遵守《公司（清盤及雜項條文）條例》—現有股東的緊密聯繫人的基石認購」一節。

(3) 有關詳情，請參閱本公告「其他／額外資料—向根據配售指引第5(1)段事先同意的一名關連客戶進行分配」一節。

身為本公司客戶／供應商的獲配發人

投資者	所分配發售股份數目	佔發售股份數目之百分比	佔全球發售後已發行H股總數之百分比	佔全球發售後已發行股本總數之百分比	關係
AKESO, INC. ／ 康方生物科技（開曼）有限公司	752,500	4.92%	0.25%	0.19%	本公司供應商並為基石投資者

## 禁售承諾

### 控股股東

姓名／名稱	於上市時需遵守禁售承諾的所持本公司股票數目	於上市時需遵守禁售承諾的所持本公司H股數目	於上市時需遵守禁售承諾佔全球發售後的已發行H股總數之百分比	於上市時需遵守禁售承諾的本公司股權之百分比	需遵守禁售承諾的最後一天
Frank Wu / 吳永謙 (「吳博士」) 備註 1	47,847,024	47,847,024	15.86%	12.06%	2025 年 12 月 22 日 (首六個月期間) 備註 2
					2026 年 6 月 22 日 (第二個六個月期間) 備註 3
Nanjing Yipu Bioscience Technology Partnership (Limited Partnership) / 南京益璞生物科技合夥企業 (有限合夥) (「南京益璞」) 備註 1	54,726,152	27,363,076	9.07%	13.79%	2025 年 12 月 22 日 (首六個月期間) 備註 2
					2026 年 6 月 22 日 (第二個六個月期間) 備註 3
Nanjing Jiminrui Biotech Partnership (Limited Partnership) / 南京吉旻瑞生物科技合夥企業 (有限合夥) (「南京吉旻瑞」) 備註 1	28,284,453	5,387,697	1.79%	7.13%	2025 年 12 月 22 日 (首六個月期間) 備註 2



姓名／名稱	於上市時需遵守禁售承諾的所持本公司股票數目	於上市時需遵守禁售承諾的所持本公司H股數目	於上市時需遵守禁售承諾佔全球發售後的已發行H股總數之百分比	於上市時需遵守禁售承諾的本公司股權之百分比	需遵守禁售承諾的最後一天
					2026年6月22日 (第二個六個月期間) 備註 3
小計	130,857,629	80,597,797	26.72%	32.98%	
<p>備註：</p> <p>(1) 截至本公告日期，吳博士、南京益鏤及南京吉旻瑞均為本公司的控股股東，擁有本公司已發行股份總數約34.29%的權益。有關控股股東的詳情，請參閱招股章程「歷史、發展及公司架構」一節。</p> <p>(2) 根據相關《上市規則》／指引資料，所規定的首六個月禁售期間於2025年12月22日結束。控股股東可於所示日期後處置或轉讓股份，前提是控股股東仍然為控股股東，惟需遵守中國《公司法》的適用規定。</p> <p>(3) 根據相關《上市規則》／指引資料，所規定的第二個六個月禁售期間於2026年6月22日結束。控股股東可於所示日期後處置或轉讓股份，前提是控股股東仍然為控股股東，惟需遵守中國《公司法》的適用規定。</p>					

首次公開發售前投資者（定義見招股章程「歷史、發展及公司架構」一節）

姓名／名稱	於上市時需遵守禁售承諾的所持本公司股票數目	於上市時需遵守禁售承諾的所持本公司H股數目	於上市時需遵守禁售承諾佔全球發售後的已發行H股總數之百分比	於上市時需遵守禁售承諾的本公司股權之百分比	需遵守禁售承諾的最後一天
Shanghai GP Healthcare Equity Investment Enterprise (Limited Partnership)	14,463,724	14,463,724	4.79%	3.64%	2026年6月22日 備註 2

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
p)／上 海金浦醫 療健康股 權投資合 夥企業 (有限合 夥) <sup>備註 1</sup>					
Shanghai GP Healthcar e Phase III Venture Capital Fund Partnershi p (Limited Partnershi p)／上 海金浦健 康三期創 業投資基 金合夥企 業(有限 合夥) <sup>備註 1</sup>	2,690,1 36	2,690,136	0.89%	0.68%	2026年6月22日 <sup>備 註 2</sup>
SDIC (Guangdo ng) Scientific and Technolo gical Achievem ent Transform ation Venture Capital	11,565, 615	11,565,615	3.83%	2.91%	2026年6月22日 <sup>備 註 2</sup>

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
Fund Partnershi p (Limited Partnershi p)／國 投（廣 東）科技 成果轉化 創業投資 基金合夥 企業（有 限合夥） 備註 1					
SDIC (Ningbo) Scientific and Technolo gical Achievem ent Transform ation Venture Capital Fund Partnershi p (Limited Partnershi p)／國 投（寧 波）科技 成果轉化 創業投資 基金合夥 企業（有 限合夥） 備註 1	10,114, 466	10,114,466	3.35%	2.55%	2026年6月22日 <sup>備 註 2</sup>

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
Shenzhen Linghui Cornersto ne Equity Investmen t Fund Partnershi p (Limited Partnershi p)／深 圳市領匯 基石股權 投資基金 合夥企業 (有限合 夥) 備註 1	7,780,5 05	7,780,505	2.58%	1.96%	2026年6月22日 備 註 2
Wuhu Xingrui Cornersto ne Equity Investmen t Partnershi p(Limited Partnershi p)／蕪 湖星睿基 石股權投 資合夥企 業(有限 合夥) 備註 1	4,836,5 29	4,836,529	1.60%	1.22%	2026年6月22日 備 註 2
Nanjing Lingyi Cornersto ne Equity Investmen t Partnershi	2,494,3 69	2,494,369	0.83%	0.63%	2026年6月22日 備 註 2

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
p (Limited Partnershi p)／南 京領益基 石股權投 資合夥企 業（有限 合夥） <small>備註 1</small>					
Shanghai Guohong Medical and Health Investmen t Center (Limited Partnershi p)／上 海國弘醫 療健康投 資中心 （有限合 夥） <small>備註 1</small>	6,857,3 15	6,857,315	2.27%	1.73%	2026年6月22日 <small>備 註 2</small>
Zhangjiag ang Guohong Jiyuan Investmen t Partnershi p (Limited Partnershi p)／張 家港國弘 紀元投資 合夥企業	4,045,8 23	4,045,823	1.34%	1.02%	2026年6月22日 <small>備 註 2</small>



姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
(有限合夥) <small>備註 1</small>					
Jingzhou Huikang Equity Investment Fund Partnership (Limited Partnership)／荊州慧康股權投資基金合夥企業(有限合夥) <small>備註 1</small>	6,834,259	6,834,259	2.27%	1.72%	2026年6月22日 <small>備註 2</small>
Structural Reform Fund, Shenzhen Guotiao Merchants and Equity Investment Fund Partnership (Limited Partnership)／深圳國調招商併購股權投資基金合夥企業(有限合夥) <small>備註 1</small>	5,404,468	5,404,468	1.79%	1.36%	2026年6月22日 <small>備註 2</small>

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
Nanjing Ennovation Raylight Venture Capital Partnershi p (Limited Partnershi p)／南 京恩然瑞 光創業投 資合夥企 業（有限 合夥） <sup>備註 1</sup>	3,337,787	1,668,894	0.55%	0.84%	2026年6月22日 <sup>備 註2</sup>
Nanjing Qiruiyoukang Venture Capital Partnershi p (Limited Partnershi p)／南 京其瑞佑 康創業投 資合夥企 業（有限 合夥） <sup>備註 1</sup>	2,022,880	1,011,440	0.34%	0.51%	2026年6月22日 <sup>備 註2</sup>
Taixing Qichen Emerging Industry Venture Capital Fund Partnershi	1,662,818	0	0.00%	0.42%	2026年6月22日 <sup>備 註2</sup>

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
p (Limited Partnershi p)／泰 興市啟辰 新興產業 創業投資 基金合夥 企業（有 限合夥） 備註 1					
Jiangsu Zhongde Services Trade Industry Investmen t Fund (Limited Partnershi p)／江 蘇中德服 貿產業投 資基金 （有限合 夥）備註 1	831,40 9	0	0.00%	0.21%	2026 年 6 月 22 日備 註 2
Trinity Zhongzhi Phase II (Tianjin) Venture Capital Center (Limited Partnershi p)／三 一眾志二 期（天 津）創業	2,718,7 07	2,718,707	0.90%	0.68%	2026 年 6 月 22 日備 註 2

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
投資中心 (有限合 夥) 備註 1					
Genecare Developm ent Limited ／ 基科 發展有限 公司 備註 1	27,610, 879	27,610,879	9.15%	6.96%	2026年6月22日 備 註 2
Future Industry Investmen t Fund II (Limited Partnershi p)／ 先 進製造產 業投資基 金二期 (有限合 夥) 備註 1	24,274, 756	24,274,756	8.05%	6.12%	2026年6月22日 備 註 2
CPE Investmen t (Hong Kong) 2021 Limited 備 註 1	21,521, 091	0	0.00%	5.42%	2026年6月22日 備 註 2
China Structural Reform Fund Corporati on Limited ／ 中國 國有企業 結構調整 基金股份	16,140, 817	16,140,817	5.35%	4.07%	2026年6月22日 備 註 2

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
有限公司 備註 1					
Nanjing Zijin Advanced Manufact ure Industry Equity Investmen t Center (Limited Partnershi p)／南 京紫金先 進製造產 業股權投 資中心 (有限合 夥) 備註 1	11,245, 844	11,245,844	3.73%	2.83%	2026年6月22日 備 註 2
Nanjing Jiangbei Medical Innovatio n Industry Fund (Limited Partnershi p)／南 京江北醫 療創新產 業基金 (有限合 夥) 備註 1	7,620,2 44	3,810,122	1.26%	1.92%	2026年6月22日 備 註 2
Nanjing InnoMed Innovatio n & Entrepren eurship	4,450,3 62	4,450,362	1.48%	1.12%	2026年6月22日 備 註 2



姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
Investmen t Partnershi p (Limited Partnershi p)／南 京鷹盟創 新創業投 資合夥企 業（有限 合夥） <sup>備註 1</sup>					
SIXTY DEGREE CAPITA L FUND II (INTERN ATIONA L), L.P. <sup>備 註 1</sup>	2,690,1 36	2,690,136	0.89%	0.68%	2026年6月22日 <sup>備 註 2</sup>
Nanjing Lvyong Ruihua Medical Health Equity Investmen t Partnershi p (Limited Partnershi p)／南 京綠涌瑞 華醫健股 權投資合 夥企業	2,494,3 69	2,494,369	0.83%	0.63%	2026年6月22日 <sup>備 註 2</sup>

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
(有限合 夥) <sup>備註 1</sup>					
CR Life Star Fund LLC <sup>備註 1</sup>	2,102,838	2,102,838	0.70%	0.53%	2026年6月22日 <sup>備註 2</sup>
Eastern Handson Holdings Limited <sup>備註 1</sup>	1,941,690	1,941,690	0.64%	0.49%	2026年6月22日 <sup>備註 2</sup>
Shanghai Guoxin Investmen t Developm ent Co., Ltd. / 上 海國鑫投 資發展有 限公司 <sup>備註 1</sup>	8,314,088	0	0.00%	2.09%	2026年6月22日 <sup>備註 2</sup>
Nanjing Baiyide Equity Investmen t Partnershi p (Limited Partnershi p) / 南 京百益德 股權投資 合夥企業 (有限合 夥) <sup>備註 1</sup>	1,662,818	831,409	0.28%	0.42%	2026年6月22日 <sup>備註 2</sup>
Wuxi Ruitong Venture Capital	831,409	831,409	0.28%	0.21%	2026年6月22日 <sup>備註 2</sup>

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
Partnershi p (Limited Partnershi p)／無 錫瑞桐創 業投資合 夥企業 (有限合 夥) 備註 1					
Nanjing Jiangbei New Area State- owned Assets Managem ent Co., Ltd.／南 京江北新 區國有資 產管理有 限公司 備註 1	4,157,0 40	500,000	0.17%	1.05%	2026年6月22日 備 註 2
BOC Capital Investmen t Holdings Co., Ltd. ／中銀 資本投資 控股有限 公司 備註 1	1,662,8 18	0	0.00%	0.42%	2026年6月22日 備 註 2
Jiangsu Dunhe Venture Capital Partnershi p (Limited	498,84 6	498,846	0.17%	0.13%	2026年6月22日 備 註 2

姓名／ 名稱	於上市 時需遵 守禁售 承諾的 所持本 公司股 票數目	於上市時需 遵守禁售承 諾的所持本 公司H股 數目	於上市時需遵守 禁售承諾佔全球 發售後的已發行 H股總數之百分 比	於上市時需遵 守禁售承諾的 本公司股權之 百分比	需遵守禁售承諾的 最後一天
Partnershi p)／江 蘇敦和創 業投資合 夥企業 (有限合 夥) <sup>備註 1</sup>					
Suzhou Dunxing Jucai Venture Capital Partnershi p (Limited Partnershi p)／蘇 州敦行聚 才創業投 資合夥企 業(有限 合夥) <sup>備註 1</sup>	332,56 4	332,564	0.11%	0.08%	2026年6月22日 <sup>備 註 2</sup>
TIF Biomedic al Fund II VCC <sup>備註 1</sup>	1,438,3 38	1,438,338	0.48%	0.36%	2026年6月22日 <sup>備 註 2</sup>
小計	228,65 1,757	183,680,629	60.89%	57.61%	
<p>備註：</p> <p>(1) 有關首次公開發售前投資者的詳情，請參閱「歷史、發展及公司架構－首次公開發售前投資－有關首次公開發售前投資者的資料」一節。</p> <p>(2) 以上的表格所示禁售期屆滿日期乃根據中國《公司法》披露。</p>					

現有股東（除了在招股章程「歷史、發展及公司架構」一節中定義的首次公開發售前投資者）

名稱	於上市時需遵守禁售承諾的所持本公司股票數目	於上市時需遵守禁售承諾的所持本公司H股數目	於上市時需遵守禁售承諾佔全球發售後的已發行H股總數之百分比	於上市時需遵守禁售承諾的本公司股權之百分比	需遵守禁售承諾的最後一天
PharmaBlock Sciences (Nanjing), Inc. / 南京藥石科技股份有限公司	22,107,247	22,107,247	7.33%	5.57%	2026年6月22日 <sup>備註1</sup>
小計	22,107,247	22,107,247	7.33%	5.57%	
備註：					
(1) 以上的表格所示禁售期屆滿日期乃根據中國《公司法》披露。					

#### 基石投資者

名稱	於上市時需遵守禁售承諾的所持本公司股票數目	於上市時需遵守禁售承諾的所持本公司H股數目 <sup>備註1</sup>	於上市時需遵守禁售承諾佔全球發售後的已發行H股總數之百分比	於上市時需遵守禁售承諾的本公司股權之百分比	需遵守禁售承諾的最後一天
Jiangbei Pharmaceutical Technology Hong Kong Limited / 江北醫藥科技（香港）有限公司	5,740,500	5,740,500	1.90%	1.45%	2025年12月22日 <sup>備註1</sup>
Akeso, Inc. / 康方生物科技（開曼）有限公司	752,500	752,500	0.25%	0.19%	2025年12月22日 <sup>備註1</sup>
Sinohsc Honest Limited / 華盛敦行有限公司	1,642,000	1,642,000	0.54%	0.41%	2025年12月22日 <sup>備註1</sup>
Pharmablock Horizon Capital	821,500	821,500	0.27%	0.21%	2025年12月



名稱	於上市時需遵守 禁售承諾的所持 本公司股票數目	於上市時需遵守 禁售承諾的所持 本公司H股數目 <sup>備註1</sup>	於上市時需 遵守禁售承 諾佔全球發 售後的已發 行H股總數 之百分比	於上市 時需遵 守禁售 承諾的 本公司 股權之 百分比	需遵守 禁售承 諾的最 後一天
Limited / 藥石 地平線資本有 限公司					22日 <sup>備註1</sup>
Kelingan (Hong Kong) Technology Co., Limited / 科瓏 安(香港)科 技有限公司	817,500	817,500	0.27%	0.21%	2025年 12月 22日 <sup>備註1</sup>
小計	9,774,000	9,774,000	3.24%	2.46%	
備註：  (1) 根據相關基石投資協議，所規定的禁售於2025年12月22日結束。基石投資者於所示日期後根據相關基石投資協議將不再被禁止處置或轉讓所認購H股。					

1.

## 承配人集中度分析

承配人	所分配H股數目	分配佔國際發售股份的百分比	分配佔發售股份總數的百分比	上市後所持股份數目	佔上市後已發行股本總數的百分比
最大	5,740,500	46.96%	37.57%	36,618,522	9.23%
前 5	9,774,000	79.96%	63.96%	63,590,679	16.02%
前 10	11,776,500	96.34%	77.07%	65,593,179	16.53%
前 25	12,147,000	99.37%	79.49%	65,963,679	16.62%

備註

\*承配人排名基於分配給承配人的H股數量。

## H股股東股權集中度分析

H股股東*	所分配H股數目	分配佔國際發售股份的百分比	分配佔發售股份總數的百分比	上市後所持H股數目	佔上市後已發行H股股本總數的百分比	上市後所持股份數目
最大	0	0.00%	0.00%	80,597,797	26.72%	130,857,629
前 5	6,562,000	53.68%	42.94%	179,388,979	59.47%	242,290,533
前 10	6,562,000	53.68%	42.94%	261,713,867	86.76%	332,929,509
前 25	11,242,000	91.97%	73.57%	297,627,673	98.66%	369,674,724

備註

\*H股股東排名基於H股股東在上市後所持的H股數量。

## 股權集中度分析

股東	所分配H股數目	分配佔國際發售股份的百分比	分配佔發售股份總數的百分比	上市後所持H股數目	上市後所持股份數目	佔上市後已發行股本總數的百分比
最大	0	0.00%	0.00%	80,597,797	130,857,629	32.97%
前 5	5,740,500	46.96%	37.57%	173,614,092	244,829,734	61.69%
前 10	6,562,000	53.68%	42.94%	249,475,140	342,211,873	86.22%
前 25	10,370,500	84.84%	67.87%	296,756,173	391,987,133	98.76%

備註

\*股東排名基於股東在上市後所持的所有類別股份數量。

### 香港公開發售的分配基準

招股章程所載的條件獲達成後，公眾認購的有效申請將按下列基準有條件分配：

所申請 H股數目	有效申請數目	分配／抽籤基準	獲分配H股佔所申請總 數的概約百分比
500	48,850	0股H股	0.80%
500	394	500股H股	
1,000	10,766	0股H股	0.54%
1,000	117	500股H股	
1,500	8,473	0股H股	0.43%
1,500	110	500股H股	
2,000	3,344	0股H股	0.36%
2,000	49	500股H股	
2,500	3,066	0股H股	0.32%
2,500	50	500股H股	
3,000	2,049	0股H股	0.29%
3,000	36	500股H股	
3,500	3,378	0股H股	0.27%
3,500	64	500股H股	
4,000	1,465	0股H股	0.24%
4,000	29	500股H股	
4,500	849	0股H股	0.23%
4,500	18	500股H股	
5,000	5,083	0股H股	0.21%
5,000	111	500股H股	
6,000	1,695	0股H股	0.19%
6,000	40	500股H股	
7,000	2,333	0股H股	0.18%
7,000	59	500股H股	
8,000	1,967	0股H股	0.16%
8,000	53	500股H股	
9,000	1,089	0股H股	0.15%
9,000	31	500股H股	
10,000	5,464	0股H股	0.14%
10,000	161	500股H股	
15,000	3,761	0股H股	0.11%
15,000	133	500股H股	
20,000	2,951	0股H股	0.10%
20,000	118	500股H股	
25,000	2,297	0股H股	0.09%
25,000	102	500股H股	
30,000	1,688	0股H股	0.08%
30,000	81	500股H股	
35,000	1,365	0股H股	0.07%

所申請 H股數目	有效申請數目	分配／抽籤基準	獲分配H股佔所申請總 數的概約百分比
35,000	71	500股H股	
40,000	1,538	0股H股	0.06%
40,000	84	500股H股	
45,000	795	0股H股	0.06%
45,000	46	500股H股	
50,000	2,346	0股H股	0.06%
50,000	142	500股H股	
60,000	1,259	0股H股	0.05%
60,000	83	500股H股	
70,000	1,170	0股H股	0.05%
70,000	82	500股H股	
80,000	1,036	0股H股	0.04%
80,000	78	500股H股	
90,000	578	0股H股	0.04%
90,000	46	500股H股	
100,000	2,425	0股H股	0.04%
100,000	200	500股H股	
150,000	1,350	0股H股	0.03%
150,000	135	500股H股	
200,000	972	0股H股	0.03%
200,000	111	500股H股	
250,000	720	0股H股	0.02%
250,000	92	500股H股	
300,000	441	0股H股	0.02%
300,000	62	500股H股	
350,000	457	0股H股	0.02%
350,000	69	500股H股	
400,000	971	0股H股	0.07%
400,000	1,238	500股H股	
450,000	131	0股H股	0.06%
450,000	170	500股H股	
500,000	290	0股H股	0.06%
500,000	383	500股H股	
600,000	157	0股H股	0.05%
600,000	215	500股H股	
700,000	85	0股H股	0.04%
700,000	120	500股H股	
764,000	659	0股H股	0.04%
764,000	931	500股H股	
總數	135,427	3,057,000股H股	

截至本公告日期，此前存放於指定代理人戶口的相關認購款項已匯回至所有香港結算參與者的賬戶。投資者如有任何查詢，請聯絡其相關投資經紀。

## 遵守《上市規則》和指引

董事確認，除《上市規則》已獲豁免及／或已取得同意外，本公司已遵守有關本公司股份配售、配發及上市的《上市規則》及指引。

董事確認，就其所深知，發行人、其控股股東、董事或包銷團成員並無直接或間接向任何承配人或公眾（視屬何情況而定）提供回佣，以及他們就所認購或購買的每股股份（或，如適用，每個單位的其他股本證券或權益（包括股本證券、房地產投資信託基金的權益、合訂證券及投資公司的證券（定義見第 21.01 條）的證券）應支付的代價相等於發行人釐定的最終發售價，另加任何應付的經紀佣金、會財局交易徵費、證監會交易徵費及交易費外。

## 其他／額外資料

### 重新分配

由於國際發售股份認購不足而香港公開發售股份獲超額認購，因此已採用招股章程「全球發售的架構 — 香港公開發售 — 重新分配」一節所披露的重新分配程序。

基於相關重新分配，香港公開發售的發售股份最終數目調整為 3,057,000 股 H 股，相當於香港公開發售下發售股份初始數目的兩倍。

### 向根據配售指引第 5(1)段事先同意的一名關連客戶進行分配

本公司已向聯交所申請且聯交所已根據配售指引第 5(1)段授予同意，允許本公司向下列關連客戶分配國際發售中的若干發售股份。向有關關連客戶分配發售股份遵守聯交所授予的同意下的所有條件。

關連分銷商	關連客戶／承配人	與關連分銷商的關係	關連客戶是否將以非酌情基準或酌情基準為獨立第三方持有發售股份的實益權益	將予認購的發售股份數目	佔全球發售下發售股份的概約百分比	佔緊隨全球發售完成後已發行股本總數的概約百分比
華泰金融控股（香港）有限公司（「華泰」）	華泰資本投資有限公司（「華泰資本投資」）	華泰及華泰資本投資為華泰證券股份有限公司的同系子公司	非酌情基準	596,500	3.90%	0.15%



附註：華泰資本投資將代表其相關客戶持有發售股份。經審慎查詢後據華泰資本投資所深知，華泰資本投資的相關客戶為華泰資本投資及華泰的獨立第三方，且兩家公司均為與華泰同一集團公司的成員公司。

### 向根據配售指引第 5(2)段事先同意的現有股東的緊密聯繫人及基石投資者分配發售股份

本公司已向聯交所申請且聯交所已根據配售指引第 5(2)段授予同意，允許本公司向現有股東的若干緊密聯繫人（作為基石投資者）分配國際發售的發售股份，惟須遵守以下條件：

- (a) 本公司將遵守上市規則第 8.08(1)及 18A.07 條的公眾持股量規定；
- (b) 江北醫藥、華盛敦行及藥石地平線各自作為全球發售的基石投資者將按相同的發售價認購及獲分配發售股份，而條款將與其他基石投資者的條款（包括受上市日期起計六個月的禁售期所規限）大致相同或不優於其他基石投資者的條款，而江北醫藥、華盛敦行及藥石地平線各自將於發售股份於上市日期開始買賣前為相關發售股份付款及全數結算代價；
- (c) 本公司及聯席保薦人確認，江北醫藥、華盛敦行及藥石地平線各自作為基石投資者概無且不會直接或間接因其與本公司的關係而於全球發售的任何分配中獲得任何優惠待遇，惟遵循指南第 2.3 章及第 4.15 章所載原則的建議基石投資下保證配額的優惠待遇則除外；及
- (d) 江北醫藥、華盛敦行及藥石地平線各自作為全球發售的基石投資者認購發售股份的詳情於本招股章程披露，而分配詳情將於本公司的配發結果公告中披露。

有關發售股份分配已遵守聯交所所授予同意下的所有條件。有關向現有股東及基石投資者分配發售股份的詳情，請參閱本公告「配發結果詳情 — 國際發售 — 已獲得豁免／同意的獲配發人」一節。

### 免責聲明

香港交易及結算所有限公司、香港聯合交易所有限公司（「**聯交所**」）及香港中央結算有限公司（「**香港結算**」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本公告不會直接或間接於或向美國（包括美國的領土及屬地、美國任何州以及哥倫比亞特區）發佈、刊發或派發。本公告並不構成亦不屬於在美國購買或認購證券的任何要約或招攬的一部分。本公告所述證券並無亦不會根據《1933 年美國證券法》（經修訂）（「美國證券法」）登記。證券不得在美國提呈發售或出售，惟獲豁免美國證券法登記規定及符合任何適用州證券法除外，證券亦不得在美國境外提呈發售或出售，惟符合美國證券法 S 規例除外。證券將不會於美國公開發售。

發售股份(1)僅可根據美國證券法的登記豁免向合資格機構買家（定義見美國證券法第144A條）提呈發售及出售；及(2)依據美國證券法S規例在美國境外以離岸交易方式提呈發售及出售。

本公告僅作參考用途，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。潛在投資者應先行閱讀藥捷安康（南京）科技股份有限公司所刊發日期為2025年6月13日的招股章程內有關下文所述全球發售的詳細資料，方決定是否投資於所提呈發售的股份。

\*發售股份的潛在投資者應注意，聯席代表（為其本身及代表香港包銷商）有權在招股章程「包銷—包銷安排及費用—香港公開發售—香港包銷協議—終止理由」一段所載的任何事件發生後，於上市日期（目前預期為2025年6月23日）上午八時正（香港時間）之前隨時終止其於香港包銷協議項下的責任且即時生效。

## 公眾持股量

緊隨全球發售完成後，合共221,068,876股H股或本公司已發行股本總額約55.70%將由公眾人士持有。因此，公眾人士持有的H股數目不低於本公司已發行股本總額的25%，符合上市規則第8.08(1)條規定的最低百分比要求。董事確認，緊隨全球發售完成後，(i)概無承配人將個別獲配售緊隨全球發售後本公司經擴大已發行股本的10%以上；(ii)緊隨全球發售後，本公司將不會新增任何主要股東；(iii)上市時三大公眾股東所持股份並未超過公眾所持股份數量的50%，符合上市規則第8.08(3)及8.24條的規定；及(iv)上市時將有至少300名股東，符合上市規則第8.08(2)條的規定。

## 開始買賣

僅於全球發售成為無條件及招股章程「包銷—包銷安排及費用—香港公開發售—終止理由」一段所述終止權利並無獲行使的情況下，H股股票方會於2025年6月23日（星期一）上午八時正（香港時間）成為有效所有權憑證。投資者如基於公開可得分配詳情在獲發H股股票前或於H股股票成為有效所有權憑證前交易H股，須自行承擔一切風險。假設全球發售於2025年6月23日（星期一）上午八時正（香港時間）或之前成為無條件，則預期H股將於2025年6月23日（星期一）上午九時正（香港時間）在聯交所開始買賣。

H股將以每手500股H股為買賣單位，H股的股份代號將為2617。

承董事會命  
藥捷安康(南京)科技股份有限公司  
董事長兼首席執行官  
吳永謙博士

香港，2025年6月20日

名列本公告相關申請的本公司董事為：(i)執行董事吳永謙博士及吳笛先生；(ii)非執行董事賈中新女士及易華博士；及(iii)獨立非執行董事李書萍先生、徐海音女士及鄭哲蘭女士。

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or any state securities law of the United States. The securities may not be offered or sold in the United States except pursuant to an exemption from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated June 13, 2025 (the “**Prospectus**”) issued by TransThera Sciences (Nanjing), Inc. (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.*

*Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.*

*In connection with the Global Offering, CLSA Limited, as stabilization manager (the “**Stabilization Manager**”), or its affiliates or any person acting for it, on behalf of the Underwriters, to the extent permitted by the applicable laws and regulatory requirements of Hong Kong or elsewhere, may effect transactions with a view to stabilizing or supporting the market price of the Shares at such price, in such amounts and in such manners as the Stabilization Manager, its affiliates or any person acting for it may determine and at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilization Manager (or its affiliates or any person acting for it) and in what the Stabilization Manager reasonably regards as the best interest of our Company, (b) may be discontinued at any time and (c) is required to be brought to an end on Friday, July 18, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).*

*Potential investors should be aware that no stabilizing action can be taken to support the price of the Shares for longer than the stabilization period, which will begin on the Listing Date, and is expected to expire on Friday, July 18, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.*

*Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date.*



**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康(南京)科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**GLOBAL OFFERING**

**Number of Offer Shares under the Global Offering : 15,281,000 H Shares**  
**Number of Hong Kong Offer Shares : 3,057,000 H Shares (as adjusted after reallocation)**  
**Number of International Offer Shares : 12,224,000 H Shares (as adjusted after reallocation)**  
**Offer Price : HK\$13.15 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Hong Kong Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars and subject to refund)**  
**Nominal value : RMB1.00 per H Share**  
**Stock code : 2617**

***Joint Sponsors, Overall Coordinators, Joint Global Coordinators,  
Joint Bookrunners and Joint Lead Managers***  
(In no particular order)



**CITIC SECURITIES**



**华泰国际**  
HUATAI INTERNATIONAL

***Overall Coordinator, Joint Global Coordinator,  
Joint Bookrunner and Joint Lead Manager***



**交銀國際**  
BOCOM International

***Joint Bookrunners and Joint Lead Managers***



**中銀國際 BOCI**



**招銀國際**  
CMB INTERNATIONAL



**浦銀國際**  
SPGB INTERNATIONAL



**TradeGo Markets**

# TRANSTHERA SCIENCES (NANJING), INC. / 藥捷安康(南京)科技股份有限公司

## ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 13 June 2025 (the “**Prospectus**”) issued by TransThera Sciences (Nanjing), Inc. (the “**Company**”).

**Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.**

### SUMMARY

Company information	
Stock code	2617
Stock short name	TRANSTHERA-B
Dealings commencement date	23 June 2025*

\*see note at the end of the announcement

Price Information	
Fixed Offer Price	HK\$13.15
Offer Shares and Share Capital	
Number of Offer Shares	15,281,000
Final Number of Offer Shares in Hong Kong Public Offering	3,057,000
Final Number of Offer Shares in International Offering	12,224,000
Number of issued Shares upon Listing	396,897,633
Proceeds	
Gross proceeds (Note)	HK\$ 200.95 million
Less: Estimated listing expenses payable based on Fixed Offer Price	HK\$ (39.61) million
Net proceeds	HK\$ 161.34 million

Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the Prospectus dated 13 June 2025.

### ALLOTMENT RESULTS DETAILS

#### HONG KONG PUBLIC OFFERING

No. of valid applications	135,427
No. of successful applications	6,114
Subscription level	3,419.87 times
Claw-back triggered	No
No. of Offer Shares initially available under the Hong Kong Public Offering	1,528,500
No. of Offer Shares reallocated from the International Offering	1,528,500
Final no. of Offer Shares under the Hong Kong Public Offering (after reallocation)	3,057,000



<b>% of Offer Shares under the Hong Kong Public Offering to the Global Offering</b>	20.00%
---	--------

*Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can refer to <https://www.hkeipo.hk/iporesult> to perform a search by name or identification number or <https://www.hkeipo.hk/iporesult> for the full list of allottees.*

## **INTERNATIONAL OFFERING**

<b>No. of placees</b>	123
<b>Subscription Level</b>	0.97 times
<b>No. of Offer Shares initially available under the International Offering</b>	13,752,500
<b>No. of Offer Shares reallocated to the Hong Kong Public Offering</b>	1,528,500
<b>Final no. of Offer Shares under the International Offering (after reallocation)</b>	12,224,000
<b>% of Offer Shares under the International Offering to the Global Offering</b>	80.00%

*The Directors confirm that, to the best of their knowledge, information and belief, save for (a) a consent under paragraph 5(2) of the Placing Guidelines granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to close associates of existing Shareholders of the Company, and (b) a consent under paragraph 5(1) of the Placing Guidelines and Chapter 4.15 of the Guide in relation to allocation of Offer Shares to a connected client granted by the Stock Exchange, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Supervisors, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Supervisors, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

The placees in the International Offering include the following:

### **Cornerstone Investors**

<b>Investor</b>	<b>No. of Offer Shares allocated</b>	<b>% of Offer Shares</b>	<b>% of total issued H Shares after the Global Offering</b>	<b>% of total issued share capital after the Global Offering</b>	<b>Existing shareholders or their close associates</b>
Jiangbei Pharmaceutical Technology (Hong Kong) Limited / 江北醫藥科技(香港)有限公司	5,740,500	37.57%	1.90%	1.45%	Yes

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Existing shareholders or their close associates</i>
Sinohsc Honest Limited / 華盛敦行有限公司	1,642,000	10.75%	0.54%	0.41%	Yes
Pharmablock Horizon Capital Limited/ 藥石地平線資本有限公司	821,500	5.38%	0.27%	0.21%	Yes
Kelingan (Hong Kong) Technology Co., Limited / 科瓏安(香港)科技有限公司	817,500	5.35%	0.27%	0.21%	No
AKESO, INC. / 康方生物科技(開曼)有限公司	752,500	4.92%	0.25%	0.19%	No
Total	9,774,000	63.96%	3.24%	2.46%	

***Allotees with Waivers/Consents Obtained***

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Relationship</i>
<b><i>Allotees with consent under paragraph 5(2) of the Placing Guidelines in relation to subscription for Shares by close associates of existing Shareholders</i></b> <sup>Note 2</sup>				
Jiangbei Pharmaceutical Technology Hong Kong Limited / 江北醫藥科技(香港)有限公司	5,740,500	1.90%	1.45% <sup>Note 1</sup>	A close associate of existing Shareholders and a Cornerstone Investor
Sinohsc Honest Limited / 華盛敦行有限公司	1,642,000	0.54%	0.41% <sup>Note 1</sup>	A close associate of existing Shareholders and a Cornerstone Investor
Pharmablock Horizon Capital Limited / 藥石地平線資本有限公司	821,500	0.27%	0.21% <sup>Note 1</sup>	A wholly-owned subsidiary of an existing Shareholder and a Cornerstone Investor



<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Relationship</i>
<b>Total</b>	<b>8,204,000</b>	<b>2.72%</b>	<b>2.07%</b>	
<b><i>Allottee with consent under paragraph 5(1) of the Placing Guidelines in relation to subscription for Shares by a connected client</i></b> <sup>Note 3</sup>				
Huatai Capital Investment Limited	596,500	0.20%	0.15%	Connected client

Notes:

- (1) Calculated based on the number of Offer Shares allocated to the respective Cornerstone Investors only, without taking into account the number of Shares held by the relevant existing Shareholders of whom such Cornerstone Investors are close associates.
- (2) Among the Cornerstone Investors, (i) Jiangbei Pharmaceutical Technology Hong Kong Limited is a close associate of Nanjing Zijin, Jiangbei Fund, Nanjing Qiruiyoukang, Jiangbei Assets Management, Taixing Qichen and Jiangsu Zhongde (each as defined in the Prospectus), which are existing Shareholders (together the “**Jiangsu Shareholders**”); (ii) Sinohsc Honest Limited is a close associate of Jiangsu Dunhe and Suzhou Duxing (each as defined in the Prospectus), which are existing Shareholders; and (iii) Pharmablock Horizon Capital Limited is a wholly-owned subsidiary of PharmaBlock (as defined in the Prospectus), an existing Shareholder. The Stock Exchange has granted a consent under Paragraph 5(2) of the Placing Guidelines to permit H Shares in the International Offering to be placed to Jiangbei Pharmaceutical Technology Hong Kong Limited, Sinohsc Honest Limited and Pharmablock Horizon Capital Limited. Please refer to the section headed “Waivers from Strict Compliance with the Listing Rules and Exemption from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance – Cornerstone Subscription by Close Associates of Existing Shareholders” of the Prospectus for details.
- (3) For details, please refer to the section headed “Others/Additional Information – Placing to a connected client with a prior consent under paragraph 5(1) of the Placing Guideline” in this announcement.

***Allottee who is customer or supplier of the Company***

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Relationship</i>
AKESO, INC. / 康方生物科技 (開曼)有限公司	752,500	4.92%	0.25%	0.19%	Supplier of the Company and a Cornerstone Investor

## LOCK-UP UNDERTAKINGS

### Controlling Shareholders

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Frank Wu / 吳永謙 ("Dr. Wu") <sup>Note 1</sup>	47,847,024	47,847,024	15.86%	12.06%	22 December 2025 (First Six-Month Period) <sup>Note 2</sup>
					22 June 2026 (Second Six Month Period) <sup>Note 3</sup>
Nanjing Yipu Bioscience Technology Partnership (Limited Partnership) / 南京益璞生物科技合夥企業(有限合夥) ("Nanjing Yipu") <sup>Note 1</sup>	54,726,152	27,363,076	9.07%	13.79%	22 December 2025 (First Six-Month Period) <sup>Note 2</sup>
					22 June 2026 (Second Six Month Period) <sup>Note 3</sup>
Nanjing Jiminrui Biotech Partnership (Limited Partnership) / 南京吉旻瑞生物科技合夥企業(有限合夥)("Nanjing Jiminrui") <sup>Note 1</sup>	28,284,453	5,387,697	1.79%	7.13%	22 December 2025 (First Six-Month Period) <sup>Note 2</sup>
					22 June 2026 (Second Six Month Period) <sup>Note 3</sup>
Subtotal	130,857,629	80,597,797	26.72%	32.98%	

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
-------------	--	--	--	--	---

*Notes:*

- (1) *As of the date of this announcement, Dr. Wu, Nanjing Yipu and Nanjing Jiminrui are the Controlling Shareholders of the Company, which are interested in approximately 34.29% of the total issued share capital of our Company. Please refer to the section headed “History, Development and Corporate Structure” in the Prospectus for details of the Controlling Shareholders.*
- (2) *In accordance with the relevant Listing Rule/guidance materials, the required lock-up for the first six-month period ends on 22 December 2025. The Controlling Shareholder may dispose of or transfer Shares after the indicated date provided that the Controlling Shareholder will not cease to be a Controlling Shareholder, subject to compliance with applicable requirements under the PRC Company Law.*
- (3) *In accordance with the relevant Listing Rule/guidance materials, the required lock-up for the second six-month period ends on 22 June 2026. The Controlling Shareholder may dispose of or transfer Shares after the indicated date provided that the Controlling Shareholder will not cease to be a Controlling Shareholder, subject to compliance with applicable requirements under the PRC Company Law.*

***Pre-IPO Investors (as defined in the “History, Development and Corporate Structure” section of the Prospectus)***

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Shanghai GP Healthcare Equity Investment Enterprise (Limited Partnership) / 上海金浦醫療健康股權投資合夥企業 (有限合夥) <sup>Note 1</sup>	14,463,724	14,463,724	4.79%	3.64%	22 June 2026 Note 2
Shanghai GP Healthcare Phase III Venture Capital Fund Partnership (Limited Partnership) / 上海金浦健康三期創業投資	2,690,136	2,690,136	0.89%	0.68%	22 June 2026 Note 2

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
基金合夥企業(有限合夥) <sup>Note 1</sup>					
SDIC (Guangdong) Scientific and Technological Achievement Transformation Venture Capital Fund Partnership (Limited Partnership) / 國投(廣東)科技成果轉化創業投資基金合夥企業(有限合夥) <sup>Note 1</sup>	11,565,615	11,565,615	3.83%	2.91%	22 June 2026 <sup>Note 2</sup>
SDIC (Ningbo) Scientific and Technological Achievement Transformation Venture Capital Fund Partnership (Limited Partnership) / 國投(寧波)科技成果轉化創業投資基金合夥企業(有限合夥) <sup>Note 1</sup>	10,114,466	10,114,466	3.35%	2.55%	22 June 2026 <sup>Note 2</sup>
Shenzhen Linghui Cornerstone Equity Investment Fund Partnership (Limited Partnership) / 深圳市領匯基石股權投資基金合夥企業(有限合夥) <sup>Note 1</sup>	7,780,505	7,780,505	2.58%	1.96%	22 June 2026 <sup>Note 2</sup>
Wuhu Xingrui Cornerstone Equity Investment Partnership(Limited Partnership) / 蕪湖星睿基石股權投資合夥企業(有限合夥) <sup>Note 1</sup>	4,836,529	4,836,529	1.60%	1.22%	22 June 2026 <sup>Note 2</sup>
Nanjing Lingyi Cornerstone Equity Investment	2,494,369	2,494,369	0.83%	0.63%	22 June 2026 <sup>Note 2</sup>

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Partnership (Limited Partnership) / (南京領益基石股權投資合夥企業(有限合夥)) <sup>Note 1</sup>					
Shanghai Guohong Medical and Health Investment Center (Limited Partnership) / 上海國弘醫療健康投資中心(有限合夥) <sup>Note 1</sup>	6,857,315	6,857,315	2.27%	1.73%	22 June 2026 <sup>Note 2</sup>
Zhangjiagang Guohong Ji yuan Investment Partnership (Limited Partnership) / 張家港國弘紀元投資合夥企業(有限合夥) <sup>Note 1</sup>	4,045,823	4,045,823	1.34%	1.02%	22 June 2026 <sup>Note 2</sup>
Jingzhou Huikang Equity Investment Fund Partnership (Limited Partnership) / 荊州慧康股權投資基金合夥企業(有限合夥) <sup>Note 1</sup>	6,834,259	6,834,259	2.27%	1.72%	22 June 2026 <sup>Note 2</sup>
Structural Reform Fund, Shenzhen Guotiao Merchants and Equity Investment Fund Partnership (Limited Partnership) / 深圳國調招商併購股權投資基金合夥企業(有限合夥) <sup>Note 1</sup>	5,404,468	5,404,468	1.79%	1.36%	22 June 2026 <sup>Note 2</sup>
Nanjing Ennovation Raylight Venture Capital Partnership (Limited Partnership) / 南京恩然瑞光創業投資合夥企業(有限合夥) <sup>Note 1</sup>	3,337,787	1,668,894	0.55%	0.84%	22 June 2026 <sup>Note 2</sup>

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Nanjing Qiruiyoukang Venture Capital Partnership (Limited Partnership) / 南京其瑞佑康創業投資合夥企業(有限合夥) <sup>Note 1</sup>	2,022,880	1,011,440	0.34%	0.51%	22 June 2026 <sup>Note 2</sup>
Taixing Qichen Emerging Industry Venture Capital Fund Partnership (Limited Partnership) / 泰興市啟辰新興產業創業投資基金合夥企業(有限合夥) <sup>Note 1</sup>	1,662,818	0	0.00%	0.42%	22 June 2026 <sup>Note 2</sup>
Jiangsu Zhongde Services Trade Industry Investment Fund (Limited Partnership) / 江蘇中德服貿產業投資基金(有限合夥) <sup>Note 1</sup>	831,409	0	0.00%	0.21%	22 June 2026 <sup>Note 2</sup>
Trinity Zhongzhi Phase II (Tianjin) Venture Capital Center (Limited Partnership) / 三一眾志二期(天津)創業投資中心(有限合夥) <sup>Note 1</sup>	2,718,707	2,718,707	0.90%	0.68%	22 June 2026 <sup>Note 2</sup>
Genecare Development Limited / 基科發展有限公司 <sup>Note 1</sup>	27,610,879	27,610,879	9.15%	6.96%	22 June 2026 <sup>Note 2</sup>
Future Industry Investment Fund II (Limited Partnership) / 先進製造產業投資基金二期(有限合夥) <sup>Note 1</sup>	24,274,756	24,274,756	8.05%	6.12%	22 June 2026 <sup>Note 2</sup>
CPE Investment (Hong Kong) 2021 Limited <sup>Note 1</sup>	21,521,091	0	0.00%	5.42%	22 June 2026 <sup>Note 2</sup>

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
China Structural Reform Fund Corporation Limited / 中國國有企業結構調整基金股份有限公司 Note 1	16,140,817	16,140,817	5.35%	4.07%	22 June 2026 Note 2
Nanjing Zijin Advanced Manufacture Industry Equity Investment Center (Limited Partnership) / 南京紫金先進製造產業股權投資中心(有限合夥) Note 1	11,245,844	11,245,844	3.73%	2.83%	22 June 2026 Note 2
Nanjing Jiangbei Medical Innovation Industry Fund (Limited Partnership) / 南京江北醫療創新產業基金(有限合夥) Note 1	7,620,244	3,810,122	1.26%	1.92%	22 June 2026 Note 2
Nanjing InnoMed Innovation & Entrepreneurship Investment Partnership (Limited Partnership) / 南京鷹盟創新創業投資合夥企業(有限合夥) Note 1	4,450,362	4,450,362	1.48%	1.12%	22 June 2026 Note 2
SIXTY DEGREE CAPITAL FUND II (INTERNATIONAL), L.P. Note 1	2,690,136	2,690,136	0.89%	0.68%	22 June 2026 Note 2
Nanjing Lvyong Ruihua Medical Health Equity Investment Partnership (Limited Partnership) / 南京綠涌瑞華醫健股權投資	2,494,369	2,494,369	0.83%	0.63%	22 June 2026 Note 2



<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
合夥企業(有限合夥) Note 1					
CR Life Star Fund LLC Note 1	2,102,838	2,102,838	0.70%	0.53%	22 June 2026 Note 2
Eastern Handson Holdings Limited Note 1	1,941,690	1,941,690	0.64%	0.49%	22 June 2026 Note 2
Shanghai Guoxin Investment Development Co., Ltd. / 上海國鑫投資發展有限公司 Note 1	8,314,088	0	0.00%	2.09%	22 June 2026 Note 2
Nanjing Baiyide Equity Investment Partnership (Limited Partnership) / 南京百益德股權投資合夥企業(有限合夥) Note 1	1,662,818	831,409	0.28%	0.42%	22 June 2026 Note 2
Wuxi Ruitong Venture Capital Partnership (Limited Partnership) / 無錫瑞桐創業投資合夥企業(有限合夥) Note 1	831,409	831,409	0.28%	0.21%	22 June 2026 Note 2
Nanjing Jiangbei New Area State-owned Assets Management Co., Ltd. / 南京江北新區國有資產管理有限公司 Note 1	4,157,040	500,000	0.17%	1.05%	22 June 2026 Note 2
BOC Capital Investment Holdings Co., Ltd. / 中銀資本投資控股有限公司 Note 1	1,662,818	0	0.00%	0.42%	22 June 2026 Note 2
Jiangsu Dunhe Venture Capital Partnership (Limited Partnership) / 江蘇敦和創業投資合夥企業(有限合夥) Note 1	498,846	498,846	0.17%	0.13%	22 June 2026 Note 2



<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Suzhou Dunxing Jucai Venture Capital Partnership (Limited Partnership) / 蘇州敦行聚才創業投資合夥企業(有限合夥) <sup>Note 1</sup>	332,564	332,564	0.11%	0.08%	22 June 2026 <sup>Note 2</sup>
TIF Biomedical Fund II VCC <sup>Note 1</sup>	1,438,338	1,438,338	0.48%	0.36%	22 June 2026 <sup>Note 2</sup>
Subtotal	228,651,757	183,680,629	60.89%	57.61%	

*Notes:*

- (1) Please refer to the section headed “History, Development and Corporate Structure — Pre-IPO Investments — Information about the Pre-IPO Investors” in the Prospectus for details of the Pre-IPO Investors.
- (2) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

***Existing Shareholders (other than the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)***

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
PharmaBlock Sciences (Nanjing), Inc. / 南京藥石科技股份有限公司	22,107,247	22,107,247	7.33%	5.57%	22 June 2026 <sup>Note 1</sup>
Subtotal	22,107,247	22,107,247	7.33%	5.57%	

*Note:*

- (1) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

## Cornerstone Investors

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i> <i>Note 1</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Jiangbei Pharmaceutical Technology Hong Kong Limited / 江北醫藥科技(香港)有限公司	5,740,500	5,740,500	1.90%	1.45%	22 December 2025 <sup>Note 1</sup>
Akeso, Inc. / 康方生物科技(開曼)有限公司	752,500	752,500	0.25%	0.19%	22 December 2025 <sup>Note 1</sup>
Sinohsc Honest Limited / 華盛敦行有限公司	1,642,000	1,642,000	0.54%	0.41%	22 December 2025 <sup>Note 1</sup>
Pharmablock Horizon Capital Limited / 藥石地平線資本有限公司	821,500	821,500	0.27%	0.21%	22 December 2025 <sup>Note 1</sup>
Kelingan (Hong Kong) Technology Co., Limited / 科瓏安(香港)科技有限公司	817,500	817,500	0.27%	0.21%	22 December 2025 <sup>Note 1</sup>
Subtotal	9,774,000	9,774,000	3.24%	2.46%	

*Note:*

(1) In accordance with the relevant cornerstone agreements, the required lock-up ends on 22 December 2025. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.

## PLACEE CONCENTRATION ANALYSIS

Places	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	5,740,500	46.96%	37.57%	36,618,522	9.23%
Top 5	9,774,000	79.96%	63.96%	63,590,679	16.02%
Top 10	11,776,500	96.34%	77.07%	65,593,179	16.53%
Top 25	12,147,000	99.37%	79.49%	65,963,679	16.62%

Notes

\* Ranking of placees is based on the number of H Shares allotted to the placees.

## H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	80,597,797	26.72%	130,857,629
Top 5	6,562,000	53.68%	42.94%	179,388,979	59.47%	242,290,533
Top 10	6,562,000	53.68%	42.94%	261,713,867	86.76%	332,929,509
Top 25	11,242,000	91.97%	73.57%	297,627,673	98.66%	369,674,724

Notes

\* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

## SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	0	0.00%	0.00%	80,597,797	130,857,629	32.97%
Top 5	5,740,500	46.96%	37.57%	173,614,092	244,829,734	61.69%
Top 10	6,562,000	53.68%	42.94%	249,475,140	342,211,873	86.22%
Top 25	10,370,500	84.84%	67.87%	296,756,173	391,987,133	98.76%

Notes

\* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

### ***BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING***

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

<b>NO. OF H SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR</b>
500	48,850	0 H Shares	0.80%
500	394	500 H Shares	
1,000	10,766	0 H Shares	0.54%
1,000	117	500 H Shares	
1,500	8,473	0 H Shares	0.43%
1,500	110	500 H Shares	
2,000	3,344	0 H Shares	0.36%
2,000	49	500 H Shares	
2,500	3,066	0 H Shares	0.32%
2,500	50	500 H Shares	
3,000	2,049	0 H Shares	0.29%
3,000	36	500 H Shares	
3,500	3,378	0 H Shares	0.27%
3,500	64	500 H Shares	
4,000	1,465	0 H Shares	0.24%
4,000	29	500 H Shares	
4,500	849	0 H Shares	0.23%
4,500	18	500 H Shares	
5,000	5,083	0 H Shares	0.21%
5,000	111	500 H Shares	
6,000	1,695	0 H Shares	0.19%
6,000	40	500 H Shares	
7,000	2,333	0 H Shares	0.18%
7,000	59	500 H Shares	
8,000	1,967	0 H Shares	0.16%
8,000	53	500 H Shares	
9,000	1,089	0 H Shares	0.15%
9,000	31	500 H Shares	
10,000	5,464	0 H Shares	0.14%
10,000	161	500 H Shares	
15,000	3,761	0 H Shares	0.11%
15,000	133	500 H Shares	
20,000	2,951	0 H Shares	0.10%
20,000	118	500 H Shares	
25,000	2,297	0 H Shares	0.09%
25,000	102	500 H Shares	
30,000	1,688	0 H Shares	0.08%

<b>NO. OF H SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR</b>
30,000	81	500 H Shares	
35,000	1,365	0 H Shares	0.07%
35,000	71	500 H Shares	
40,000	1,538	0 H Shares	0.06%
40,000	84	500 H Shares	
45,000	795	0 H Shares	0.06%
45,000	46	500 H Shares	
50,000	2,346	0 H Shares	0.06%
50,000	142	500 H Shares	
60,000	1,259	0 H Shares	0.05%
60,000	83	500 H Shares	
70,000	1,170	0 H Shares	0.05%
70,000	82	500 H Shares	
80,000	1,036	0 H Shares	0.04%
80,000	78	500 H Shares	
90,000	578	0 H Shares	0.04%
90,000	46	500 H Shares	
100,000	2,425	0 H Shares	0.04%
100,000	200	500 H Shares	
150,000	1,350	0 H Shares	0.03%
150,000	135	500 H Shares	
200,000	972	0 H Shares	0.03%
200,000	111	500 H Shares	
250,000	720	0 H Shares	0.02%
250,000	92	500 H Shares	
300,000	441	0 H Shares	0.02%
300,000	62	500 H Shares	
350,000	457	0 H Shares	0.02%
350,000	69	500 H Shares	
400,000	971	0 H Shares	0.07%
400,000	1,238	500 H Shares	
450,000	131	0 H Shares	0.06%
450,000	170	500 H Shares	
500,000	290	0 H Shares	0.06%
500,000	383	500 H Shares	
600,000	157	0 H Shares	0.05%
600,000	215	500 H Shares	
700,000	85	0 H Shares	0.04%
700,000	120	500 H Shares	
764,000	659	0 H Shares	0.04%
764,000	931	500 H Shares	
Total	135,427	3,057,000 H Shares	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

## **COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, no rebate has been, directly or indirectly, provided by the issuer, its controlling shareholder(s), directors or syndicate members to any placees or the public (as the case may be) and the consideration payable by them for each share (or, where applicable, each unit of other equity securities or interests (which include equity securities, interests in a REIT, stapled securities and securities of an investment company (as defined in rule 21.01)) of the issuer subscribed for or purchased by them is the same as the final offer price determined by the issuer, in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

## **OTHERS/ADDITIONAL INFORMATION**

### **Reallocation**

As the International Offer Shares are undersubscribed and the Hong Kong Public Offer Shares are oversubscribed, the reallocation procedure as disclosed in the section headed "Structure of the Global Offering — The Hong Kong Public Offering — Reallocation" of the Prospectus has been applied.

As a result of such reallocation, the final number of Offer Shares under the Hong Kong Public Offering is adjusted to 3,057,000 H Shares, representing two times of the initial number of Offer Shares under the Hong Kong Public Offering.

### **Placing to a connected client with a prior consent under paragraph 5(1) of the Placing Guidelines**

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate certain Offer Shares in the International Offering to a connected client listed below. The allocation of Offer Shares to such connected client is in compliance with all the conditions under the consent granted by the Stock Exchange.

Connected Distributor	Connected Client/ Placee	Relationship with the Connected Distributor	Whether the connected client will hold beneficial interests of Offer Shares on a non-discretionary or discretionary basis for	Number of Offer Shares to be subscribed	Approximate % to the Offer Shares under the Global Offering	Approximate % to the total issued share capital immediately following completion of the Global Offering

			independent third parties			
Huatai Financial Holdings (Hong Kong) Limited (“Huatai”)	Huatai Capital Investment Limited (“HTCI”)	Huatai and HTCI are fellow subsidiaries of Huatai Securities Co., Ltd.	Non-discretionary basis	596,500	3.90%	0.15%

*Note: HTCI will hold the Offer Shares on behalf of its underlying client. To the best knowledge of HTCI after due enquiry, the underlying client of HTCI is an independent third party of HTCI and Huatai and the companies which are members of the same group of companies as Huatai.*

### **Allocations of Offer Shares to close associates of existing Shareholders and Cornerstone Investors with a consent under paragraph 5(2) of the Placing Guidelines**

The Company has applied to, and the Stock Exchange has granted, a consent under paragraph 5(2) of the Placing Guidelines for permitting the Company to allocate Offer Shares in the International Offering to certain close associates of existing shareholders as cornerstone investors, subject to the following conditions:

- (a) the Company will comply with the public float requirements of Rules 8.08(1) and 18A.07 of the Listing Rules;
- (b) the Offer Shares to be subscribed by and allocated to each of Jiangbei Pharmaceutical, Sinohsc Honest and Pharmablock Horizon as Cornerstone Investors under the Global Offering will be at the same Offer Price and on substantially the same terms as, or no more favorable than, the terms of other cornerstone investors (including being subject to a lock-up period of six months from the Listing Date) and each of Jiangbei Pharmaceutical, Sinohsc Honest and Pharmablock Horizon shall pay and settle in full the consideration for the relevant Offer Shares before dealings commence on the Listing Date;
- (c) the Company and the Joint Sponsors confirm that no preferential treatment has been, nor will be, directly or indirectly, given to each of Jiangbei Pharmaceutical, Sinohsc Honest and Pharmablock Horizon as Cornerstone Investors by virtue of its relationship with the Company in any allocation in the Global Offering, other than the preferential treatment of assured entitlement under the Proposed Cornerstone Investments which follows the principles set out in the Chapters 2.3 and 4.15 of the Guide; and
- (d) details of the subscription of the Offer Shares by each of Jiangbei Pharmaceutical, Sinohsc Honest and Pharmablock Horizon as Cornerstone Investors under the Global Offering are disclosed in this prospectus, and details of the allocation will be disclosed in the allotment results announcement of our Company.

Such allocations of Offer Shares are in compliance with all the conditions under the consent granted by the Stock Exchange. For details of the allocations of Offer Shares to existing Shareholders and Cornerstone Investors, please refer to the section headed “Allotment Results Details – International Offer – Allotees with Waivers/Consents Obtained” in this announcement.



## DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated 13 June 2025 issued by TransThera Sciences (Nanjing), Inc. for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.*

*\*Potential investors of the Offer Shares should note that the Joint Representatives (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on 23 June 2025).*

## PUBLIC FLOAT

Immediately following the completion of the Global Offering, an aggregate of 221,068,876 H Shares or approximately 55.70% of the total issued share capital of the Company will be held in the public hands. Therefore, the number of H Shares in the public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08(1) of the Listing Rules. The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the Shares held in the public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.



## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, June 23, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk. Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Monday, June 23, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Monday, June 23, 2025 (Hong Kong time).

The H Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will be 2617.

By order of our Board  
**TransThera Sciences (Nanjing), Inc.**  
**藥捷安康(南京)科技股份有限公司**  
**Dr. Frank Wu**  
*Chairman and Chief Executive Officer*

Hong Kong, June 20, 2025

*The directors of the Company named in the application to which this announcement relates are: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.*